Course Description:
For drug innovators, CDMOs, Over the Counter (OTC), or generics manufacturers, knowing how and when to adopt pharmaceutical continuous manufacturing (PCM) can speed time to market for your products, increase yield, reduce losses, and help your business thrive. This webinar presents the specific business case for each market segment when integrating advanced manufacturing technologies, including barriers to adoption, and supported by real world examples.
Innovator Companies
Improve the cost profile of an existing product or solve specific issues with a product. Developing a new product in a continuous process can speed time to market and reduce transfer and commercial manufacturing costs.
Generics, OTC, Nutraceutical Companies
To deal with low margins, high competition, and a large and diverse portfolio, flexible batch size PCM helps cope with unpredictable volumes; strong process knowledge minimizes reactive “putting out fires” and product loss.
CDMOs
Outsourcing bridges the period of uncertainty in bringing a product to market for innovators or lowers the investment risk for companies ready to adopt a continuous manufacturing process. CDMOs need a flexible solution that helps them serve a broad customer base. We discuss how this can be done and the best moment to start.
Who should participate:
Drug manufacturing, pharmaceutical manufacturing, biologics organizations; Job function: quality assurance (QA), quality control (QC), operations managers, quality management, pharmaceutical quality directors, MHA, MPH; Decision-makers for PCM – innovators, OTC, CDMOs; VP R & D; Manufacturing; Senior R & D; head of technology; CTO; COO; Technical services; technical operations; CFO; Finance
Though this course is being made available on USP’s
Education site, the course content was developed by Pharmatech Associates, a
USP company. USP has not independently reviewed or verified the accuracy
of the course content.